• Je něco špatně v tomto záznamu ?

Percentage of eosinophils with surface CD44 and levels of eosinophil cationic protein in the peripheral blood in children with bronchial asthma and their changes after montelukast therapy

Kopriva F, Szotkowská J, Ordeltová M, Zápalka M.

. 2006 ; 27 (4) : 378-382.

Jazyk angličtina Země Spojené státy americké

Perzistentní odkaz   https://www.medvik.cz/link/bmc07523510
E-zdroje Online

NLK ProQuest Central od 1996-01-01 do 2012-05-31
Medline Complete (EBSCOhost) od 2003-01-01
Health & Medicine (ProQuest) od 1996-01-01 do 2012-05-31
Public Health Database (ProQuest) od 1996-01-01 do 2012-05-31

Bronchial asthma (BA) is chronic inflammation of the respiratory tract with a role played by a variety of cells, particularly mast cells, eosinophils (Eo), and T lymphocytes. The serum levels of Eo cationic protein (S-ECP) reflect the severity of bronchial inflammation and the level of bronchial hyperreactivity in asthma patients. One of the most important adhesion molecules is CD44. We examined S-ECP, the percentage of Eo with surface CD44 expression (EoCD44), and Eo count in the peripheral blood of newly diagnosed pediatric atopic patients with intermittent and persistent mild BA according to the Global Iniative for Asthma 2002, in a proportion of patients 3 months after initiation of montelukast therapy. Ninety-seven children with BA had their medical history taken, and S-ECP, with the percentage of EoCD44 determined by direct fluorescence from whole blood using flow cytometry with a Coulter EPICS XL cytometer, and Eo count, total serum immunoglobulin E levels (S-IgE) were determined. Therapy with montelukast (5 mg daily) was started in 23 children. Three months after the first collection, a second S-ECP level and EoCD44 count determinations were made. An inverse correlation between S-ECP and EoCD44 (-0.602; p < 0.0001) was found in the 97 children with BA. In the 23 children receiving montelukast we documented inverse correlation of fluctuation on S-ECP and EoCD44 after 3 months. These results were not significant. An inverse correlation between S-ECP and percent of EoCD44 was established in the 97 children with asthma before therapy initiation. The lower percentage of EoCD44 in peripheral blood in asthmatic children is due to Eo inflammation activity and attests to massive Eo invasion into the airways. Determination of the percentage proportion of EoCD44 is another potential indirect marker of the multiple features of Eo inflammation.

000      
00000naa 2200000 a 4500
001      
bmc07523510
003      
CZ-PrNML
005      
20111210135456.0
008      
090519s2006 xxu e eng||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kopřiva, František, $d 1956- $7 xx0012473
245    10
$a Percentage of eosinophils with surface CD44 and levels of eosinophil cationic protein in the peripheral blood in children with bronchial asthma and their changes after montelukast therapy / $c Kopriva F, Szotkowská J, Ordeltová M, Zápalka M.
314    __
$a Department of Pediatrics, Palacký University Medical School and University Hospital, Puskinova 6, 775 20 Olomouc, Czech Republic. Koprivaf@FNOL.cz
520    9_
$a Bronchial asthma (BA) is chronic inflammation of the respiratory tract with a role played by a variety of cells, particularly mast cells, eosinophils (Eo), and T lymphocytes. The serum levels of Eo cationic protein (S-ECP) reflect the severity of bronchial inflammation and the level of bronchial hyperreactivity in asthma patients. One of the most important adhesion molecules is CD44. We examined S-ECP, the percentage of Eo with surface CD44 expression (EoCD44), and Eo count in the peripheral blood of newly diagnosed pediatric atopic patients with intermittent and persistent mild BA according to the Global Iniative for Asthma 2002, in a proportion of patients 3 months after initiation of montelukast therapy. Ninety-seven children with BA had their medical history taken, and S-ECP, with the percentage of EoCD44 determined by direct fluorescence from whole blood using flow cytometry with a Coulter EPICS XL cytometer, and Eo count, total serum immunoglobulin E levels (S-IgE) were determined. Therapy with montelukast (5 mg daily) was started in 23 children. Three months after the first collection, a second S-ECP level and EoCD44 count determinations were made. An inverse correlation between S-ECP and EoCD44 (-0.602; p < 0.0001) was found in the 97 children with BA. In the 23 children receiving montelukast we documented inverse correlation of fluctuation on S-ECP and EoCD44 after 3 months. These results were not significant. An inverse correlation between S-ECP and percent of EoCD44 was established in the 97 children with asthma before therapy initiation. The lower percentage of EoCD44 in peripheral blood in asthmatic children is due to Eo inflammation activity and attests to massive Eo invasion into the airways. Determination of the percentage proportion of EoCD44 is another potential indirect marker of the multiple features of Eo inflammation.
650    _2
$a acetáty $x aplikace a dávkování $x terapeutické užití $7 D000085
650    _2
$a mladiství $7 D000293
650    _2
$a antigeny CD44 $x krev $7 D018960
650    _2
$a bronchiální astma $x farmakoterapie $x krev $7 D001249
650    _2
$a předškolní dítě $7 D002675
650    _2
$a dítě $7 D002648
650    _2
$a rozvrh dávkování léků $7 D004334
650    _2
$a eozinofilní kationtový protein $x krev $7 D047150
650    _2
$a eozinofily $7 D004804
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a imunoglobulin E $x krev $7 D007073
650    _2
$a počet leukocytů $7 D007958
650    _2
$a antagonisté leukotrienů $x aplikace a dávkování $x terapeutické užití $7 D020024
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a chinoliny $x aplikace a dávkování $x terapeutické užití $7 D011804
700    1_
$a Szotkowská, Jarmila $7 xx0103477
700    1_
$a Ordeltová, Marta $7 xx0100431
700    1_
$a Zápalka, Martin $7 xx0096385
773    0_
$w MED00005058 $t Allergy and asthma proceedings $g Roč. 27, č. 4 (2006), s. 378-382 $x 1088-5412
910    __
$a ABA008 $b x $y 9
990    __
$a 20090519102933 $b ABA008
991    __
$a 20090618092743 $b ABA008
999    __
$a ok $b bmc $g 654490 $s 507796
BAS    __
$a 3
BMC    __
$a 2006 $b 27 $c 4 $d 378-382 $i 1088-5412 $m Allergy and asthma proceedings $x MED00005058
LZP    __
$a 2009-B2/dkme

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...